Key regions: United Kingdom, Brazil, Europe, France, Canada
The Anti-Fibrinolytic Drugs market in Burundi has been experiencing steady growth in recent years.
Customer preferences: Patients suffering from bleeding disorders such as hemophilia and von Willebrand disease are the primary consumers of Anti-Fibrinolytic Drugs. These drugs are also used during surgeries to prevent excessive bleeding. In Burundi, the demand for Anti-Fibrinolytic Drugs is driven by the increasing prevalence of bleeding disorders and the growing number of surgeries being performed in the country.
Trends in the market: The Anti-Fibrinolytic Drugs market in Burundi is witnessing a trend of increasing adoption of generic drugs due to their affordability. The market is also seeing a rise in the number of market players, leading to increased competition and innovation. However, the market is still dominated by a few major players due to their strong brand recognition and established distribution networks.
Local special circumstances: Burundi is a low-income country with limited healthcare resources. The healthcare system is primarily funded by the government, and private healthcare facilities are scarce. This has led to a high burden of disease and limited access to healthcare for many Burundians. The lack of healthcare infrastructure and resources has also contributed to the limited availability of Anti-Fibrinolytic Drugs in the country.
Underlying macroeconomic factors: The Burundian economy has been growing at a slow pace due to political instability, limited infrastructure, and weak governance. The country heavily relies on agriculture, which accounts for over 90% of the country's exports. The low-income levels and limited healthcare resources have also contributed to the slow growth of the Anti-Fibrinolytic Drugs market in Burundi.In conclusion, the Anti-Fibrinolytic Drugs market in Burundi is growing steadily, driven by the increasing prevalence of bleeding disorders and the growing number of surgeries being performed in the country. However, the market is facing challenges due to the limited healthcare resources and infrastructure in the country. The trend of increasing adoption of generic drugs and rising competition is expected to continue in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
